Is rituximab noninferior to ocrelizumab for suppressing MRI-detected disease activity in newly diagnosed relapsing multiple sclerosis?
AFFINITY
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial
Multiple Sclerosis Journal · 2025
Bottom Line: Opicinumab 750 mg IV q4w did not meet its primary endpoint (Overall Disability Response Score) at 72 weeks, although a multicomponent CDI endpoint that incorporated SDMT and a prespecified subgroup with baseline EDSS ≥3.0 favored opicinumab; the safety profile was generally similar to placebo.